Baden-Württemberg is the most innovative region in Europe. The figures for 2009 show that 4.8 percent of the gross domestic product (16.4 billion euros) is being invested in research and development. With its versatile, outstandingly efficient research in biotechnology and the life sciences, Baden-Württemberg has a unique trump card in terms of the economic development of the life sciences in the state.
Intensive cooperation between the engineering-driven sectors and the biotechnology sector is a prerequisite for driving forward automation in the field of biotechnology. The Engineering – Life Sciences – Automation (ELSA) cluster initiative of BioRegio STERN Management GmbH aims to promote cross-industry cooperation. A study entitled ‘Biotech meets Autotech’, which was carried out as part of the ELSA project, provides insights into the current status of cooperation and the potential offered by closer collaboration. more
Curetis AG
EUR 12.5 million in Series B round
On the 22nd April 2013 the Curetis AG in Holzgerlingen announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners. Dr. Alexander Asam of HBM will join Curetis’ supervisory board. Curetis will use the proceeds for the next phase of commercial and operational growth. more
On the 22nd April 2013 the Curetis AG in Holzgerlingen announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners. Dr. Alexander Asam of HBM will join Curetis’ supervisory board. Curetis will use the proceeds for the next phase of commercial and operational growth.
Intensive cooperation between the engineering-driven sectors and the biotechnology sector is a prerequisite for driving forward automation in the field of biotechnology. The Engineering – Life Sciences – Automation (ELSA) cluster initiative of BioRegio STERN Management GmbH aims to promote cross-industry cooperation. A study entitled ‘Biotech meets Autotech’, which was carried out as part of the ELSA project, provides insights into the current status of cooperation and the potential offered by closer collaboration.
The annual ”Networking Breakfast” was held at the Chicago Club on 23rd April 2013 on the occasion of the 2013 BIO International Convention, the global event for biotechnology. As part of the event, Heidelberg Technology Park (HTP) and the University Technology Park in Chicago unveiled an expanded partnering programme. Around 70 participants from 12 countries used the exclusive setting to make new international contacts, renew old ones and exchange thoughts on cooperation possibilities.
Placebo research at Tübingen University is part of a German network that is a world leader in the field. One of the research priorities relates to the perception of pain and the underlying neurobiological mechanisms.
The annual TMF conference in Heidelberg dealt with the need for integrated science infrastructures for the advancement of medical research. The major focus was on quality criteria for medical biomaterial banks and the establishment of the German Biobank Registry as the core of a central IT infrastructure, with the overall aim of creating the right conditions for resource-saving medical research excellence in Germany.
Over the last few years, the Hertie Institute for Clinical Brain Research in Tübingen has established a comprehensive biobank for use in neurological research. The biobank is available to scientists from research institutions and companies working on research into neurological diseases such as Parkinson’s and Alzheimer’s with the aim of finding new options for the diagnosis and therapy of such diseases.
Between September 2012 to February 2013, I spent six months of practical training in Prof. Weihong Jiang’s group at the Shanghai Institute for Biological Sciences of the Chinese Academy of Sciences. A grant from the Baden-Württemberg Ministry of Science, Research and the Arts enabled me not only to gain valuable practical experience, but also gave me an in-depth view into Chinese culture and life in Shanghai.
The control of the behaviour of individual neurons simply by switching light stimuli on and off sends neuroscientists into raptures as it reveals insights into as yet hidden and complicated processes in the brain. Thanks to optogenetics, this particular science fiction became reality a few years ago. Working with researchers from the Bernstein Center at the University of Freiburg and the Friedrich Miescher Institute for Biomedical Research in Basel, scientists in the teams of Dr. Birthe Rubehn and Prof. Dr. Thomas Stieglitz in the Department of Microsystems Engineering (IMTEK) have developed a multimodal implant which allows the genetic modulation, control and measurement of cell activity.
At it’s New Year reception, Biberach University of Applied Sciences outlined the university’s success: the establishment of its biotechnology programme is going smoothly and student interest remains steady. Biberach also has a successful track record of acquiring third-party funding and has established new national and international cooperations.
The Human Brain Project has been granted funding under the EU’s multi-billion euro competition, Future and Emerging Technolgies (FET). The project will receive funds of over one billion euros for a period of ten years and endeavour to simulate the human brain using newly developed supercomputers.
The internationally renowned biotechnologist Prof. Dr. Rolf Schmid has been acting as the government’s coordinator for life science issues in Asian countries since 2009. In an interview with BIOPRO, Prof. Schmid addresses the potentials of scientific and economic cooperation.